Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc., filed a statement of changes in beneficial ownership on November 4, 2026, disclosing the sale of 7,195 shares of common stock on November 2, 2026.

Key Highlights

  • Reporting person: Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc.
  • First sale: 6,995 shares of common stock disposed of on November 2, 2026, at a weighted average price of $26.3779 per share, with individual transaction prices ranging from $25.91 to $26.87 per share.
  • Second sale: 200 shares of common stock disposed of on November 2, 2026, at a weighted average price of $26.9913 per share, with individual transaction prices ranging from $26.96 to $27.03 per share.
  • Remaining holdings: Following both transactions, Ticho directly held 11,864 shares of common stock.
  • 10b5-1 plan: Both sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  • Exchange and ticker: Stoke Therapeutics, Inc. trades under NASDAQ:STOK.

Ticho's November 2 Share Sales Under a Pre-Established Trading Plan

According to the filing, Barry Ticho, who serves as Chief Medical Officer of Stoke Therapeutics, Inc., a clinical-stage biopharmaceutical company, disposed of a total of 7,195 shares of common stock in two separate transactions on November 2, 2026. Both transactions carried transaction code "S," indicating open-market sales, and both were conducted on a direct ownership basis.

The filing disclosed that the first transaction involved 6,995 shares sold at a weighted average price of $26.3779, with individual sale prices ranging from $25.91 to $26.87 per share inclusive. The second transaction covered 200 shares at a weighted average price of $26.9913, with individual prices ranging from $26.96 to $27.03 per share. The filing noted that full information on the number of shares sold at each separate price within those ranges is available upon request to the issuer, any security holder, or SEC staff.

Both sales were executed pursuant to a Rule 10b5-1 trading plan that Ticho adopted on November 19, 2025, according to the filing. Following the completion of both reported transactions, Ticho's direct beneficial ownership in Stoke Therapeutics common stock stood at 11,864 shares, as stated in the filing. The filing was signed by Jonathan Allan as Attorney-in-Fact on November 4, 2026.

What Was Disclosed

The filing reported two open-market sales of Stoke Therapeutics common stock by Chief Medical Officer Barry Ticho on November 2, 2026, totaling 7,195 shares sold under a pre-established Rule 10b5-1 plan, leaving Ticho with direct beneficial ownership of 11,864 shares.